Photo for representational purpose only. - File photo
New Delhi, June 17
Indian vaccine maker Bharat Biotech’s Covaxin, the whole-virion inactivated Covid-19 vaccine, has proven to be safe, well-tolerated and highly immunogenic in paediatric subjects aged 2 to 18 years in Phase 2 and 3 studies.
The safety and efficacy study has been published in Lancet Infectious Diseases, a peer reviewed high impact factor journal.
The research shows Bharat Biotech conducted Phase II/III, open-label and multicentre study to evaluate the safety, reactogenicity and immunogenicity of Covaxin in healthy children and adolescents in 2-18 years of age group. The clinical trial in the paediatric population between June 2021 and September 2021 showed safety, less reactogenic and robust immunogenicity.
NTAGI for reducing booster dose gap
The National Technical Advisory Group on Immunisation has recommended reducing the gap between the second dose of the Covid vaccine and the booster dose from the current nine to six months. TNS
The Tribune News Service brings you the latest news, analysis and insights from the region, India and around the world. Follow the Tribune News Service for a wide-ranging coverage of events as they unfold, with perspective and clarity.
Join Whatsapp Channel of The Tribune for latest updates.
Most Read In 24 Hours
Don't Miss
View All
Top News
2 CRPF personnel killed in militant attack in Manipur
The militants attacked an IRBn (India Reserve Battalion) cam...
Arjuna awardee CRPF DIG officer Khajan Singh guilty of sexually harassing colleagues; faces removal
Khajan Singh, who is currently stationed in Mumbai, has yet ...
63% voting in 2nd phase, highest 79.46% in Tripura
Jammu sees 71.91% turnout | Lowest 54.85% in UP
SC’s thumbs up to EVMs, junks PILs seeking return of paper ballot system
Rejects demand for verifying 100% votes with VVPAT slips
